All In Biotech

Drug Trial Radar · NCT04305041

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jun 26, 2020

Primary completion

Aug 25, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.

Conditions

  • Melanoma

Interventions

  • PembrolizumabBiological

    Administered via IV infusion at a specified dose on specified days

  • QuavonlimabBiological

    Administered via IV infusion at a specified dose on specified days

  • VibostolimabBiological

    Administered via IV infusion at a specified dose on specified days

  • LenvatinibDrug

    Administered via oral capsules at a specified dose on specified days

  • ATRADrug

    Administered via oral capsules at a specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 39 months
  2. Percentage of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 35 months
  3. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)Time frame: Up to approximately 59 months
  4. ORR Per RECIST 1.1 With 90% CITime frame: Up to approximately 59 months

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute ( Site 1009)

    Los Angeles, California

  • UCLA Hematology & Oncology ( Site 1004)

    Los Angeles, California

  • Providence Saint John's Health Center ( Site 1010)

    Santa Monica, California

  • University of Colorado, Anschutz Cancer Pavilion ( Site 1012)

    Aurora, Colorado

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022)

    Baltimore, Maryland

  • NYU Clinical Cancer Center ( Site 1002)

    New York, New York

  • Duke Cancer Institute ( Site 1005)

    Durham, North Carolina

  • Martha Morehouse Tower ( Site 1020)

    Columbus, Ohio

  • Oregon Health & Science University ( Site 1013)

    Portland, Oregon

  • University of Pennsylvania Abramson Cancer Center ( Site 1008)

    Philadelphia, Pennsylvania

  • West Cancer Center - East Campus ( Site 1014)

    Germantown, Tennessee

  • University of Texas MD Anderson Cancer Center ( Site 1006)

    Houston, Texas

  • Inova Schar Cancer Institute ( Site 1011)

    Fairfax, Virginia

  • Calvary Mater Newcastle-Medical Oncology ( Site 1404)

    Waratah, New South Wales, Australia

  • Melanoma Institute Australia ( Site 1402)

    Wollstonecraft, New South Wales, Australia

  • Tasman Oncology Research Pty Ltd ( Site 1403)

    Southport, Queensland, Australia

  • Fiona Stanley Hospital ( Site 1401)

    Murdoch, Western Australia, Australia

  • A.P.H. Paris, Hopital Saint Louis ( Site 1107)

    Paris, France

  • Hopital La Timone ( Site 1103)

    Marseille, Bouches-du-Rhone, France

  • Hopital Saint Andre ( Site 1108)

    Bordeaux, Gironde, France

  • Institut Claudius Regaud ( Site 1105)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 1101)

    Villejuif, Île-de-France Region, France

  • Centre Hospitalier Lyon Sud ( Site 1102)

    Pierre-Bénite, Rhone, France

  • HaEmek Medical Center ( Site 1703)

    Afula, Israel

  • Rambam Health Care Campus-Oncology ( Site 1704)

    Haifa, Israel

  • Hadassah Ein Karem Jerusalem ( Site 1702)

    Jerusalem, Israel

  • Chaim Sheba Medical Center ( Site 1701)

    Ramat Gan, Israel

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399)

    Milan, Italy

  • Istituto Europeo di Oncologia ( Site 1301)

    Milan, Italy

  • Istituto Nazionale Tumori Fondazione Pascale ( Site 1302)

    Naples, Italy

  • Istituto Oncologico Veneto IRCCS ( Site 1355)

    Padova, Italy

  • Policlinico Le Scotte - A.O. Senese ( Site 1377)

    Siena, Italy

  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE-Clinical Trials Unit ( Site 1865)

    Port Elizabeth, Eastern Cape, South Africa

  • Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603)

    Geneva, Canton of Geneva, Switzerland

  • CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)

    Lausanne, Canton of Vaud, Switzerland

  • Universitaetsspital Zuerich ( Site 1601)

    Zuerich Flughafen, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.